Usp9x inhibitors

A compound represented by Formula (I):

• or optionally by a formula with a linear backbone structure obtained by breaking a carbon-carbon or carbon-nitrogen single bond on the cyclic backbone of Formula (I) at any site, and pharmaceutically acceptable salts thereof,
• wherein R1 and R10 are each independently selected from H, 2H, and substituted or unsubstituted alkyl;
• R2, R3, R4, R6, and R7 are each independently selected from H, 2H, halogen, substituted or unsubstituted alkyl, and substituted or unsubstituted alkoxy;
• and optionally, R3 and R4 together form a substituted or unsubstituted 5- or 6-membered heterocyclic ring;
• R5 and R9 are each independently selected from H, 2H, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, and one or more aryl substituents, such as halogen;
• R8 is absent, or substituted or unsubstituted 1- to 4-carbon alkylene;
• R11 is a hydrophobic alkyl selected from substituted or unsubstituted alkyl, and substituted or unsubstituted cycloalkyl;
• Z1, Z2, and Z3 are each independently selected from CH and N;
• X1 is selected from —O—, —S—, —NH—, —CH2—;
• X2 is absent, or selected from -L-NRA—, -L-NRAC(O)—, -L-C(O)—, -L-OC(O)—, -L-C(O)O—, -L-CH(COORA)—, -L-C(O)NRA-L-, -L-C(O)NRAC(O)—, wherein RA is selected from H, 2H, substituted or unsubstituted alkyl;
• and optionally, RA, R8, and X2 together with the aryl to which R8 is attached to form a substituted or unsubstituted 5- or 6-membered heterocyclic ring;
• L is a linker group —(CH2)nCRBRC(CH2)n—, wherein RB and RC are each independently selected from H, 2H, substituted or unsubstituted alkyl;
• or RB and RC together with the carbon to which they are attached form a substituted or unsubstituted C3-C6 cycloalkyl, or a substituted or unsubstituted 3- to 6-membered heterocyclic ring;
• and wherein each n is independently 0, 1, or 2;
• and m=0, 1, 2, 3, or 4.